[13] In March 2021, rimegepant was approved for medical use in the United Arab Emirates and in Israel.

[4] In the United Kingdom, rimegepant is approved by NICE for the prophylaxis and treatment of acute migraine in adults.

[8][10][9] Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist.

[11] Rimegepant was developed by Biohaven Pharmaceuticals, which markets the drug in the United States after receiving FDA approval in February 2020.

[20] Marketing American singer, songwriter and actress Lady Gaga is featured in advertisements for rimegepant, under the Nurtec ODT brand.